Advertisement


Claire Harrison, MD, DM, on Myelofibrosis: Fedratinib as First-Line Therapy After Prior Ruxolitinib

EHA 2021 Virtual Congress

Advertisement

Claire Harrison, MD, of Guy’s and St. Thomas’ Hospital, discusses survival results from the JAKARTA and JAKARTA2 trials, which showed that fedratinib, an oral JAK2 inhibitor, significantly improved progression-free survival vs placebo as a first-line treatment for patients with myelofibrosis (Abstract S203).



Related Videos

Hematologic Malignancies
Immunotherapy

Efstathios Kastritis, MD, on Amyloidosis: Standard of Care Plus Daratumumab

Efstathios Kastritis, MD, of the University of Athens, discusses updated phase III results from the ANDROMEDA study of patients with newly diagnosed light chain amyloidosis. The trial further supports the use of daratumumab plus VCd (bortezomib, cyclophosphamide, and dexamethasone), which was shown to be clinically superior to VCd alone (Abstract S189).

Lymphoma
Immunotherapy

Martin Hutchings, MD, PhD, on Hodgkin Lymphoma: Brentuximab Vedotin With Chemotherapy

Martin Hutchings, MD, PhD, of Copenhagen University Hospital, discusses a 5-year update of the phase III ECHELON-1 study, which suggested brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine benefits patients with previously untreated stage III or IV classical Hodgkin lymphoma (Abstract S205).

Multiple Myeloma
Immunotherapy

Philippe Moreau, MD, on Newly Diagnosed Multiple Myeloma: Daratumumab Maintenance vs Observation

Philippe Moreau, MD, of University Hospital Hôtel-Dieu, discusses findings from the CASSIOPEIA trial, Part 1, on daratumumab maintenance vs observation in patients with newly diagnosed multiple myeloma who have been treated with bortezomib, thalidomide, and dexamethasone, with or without daratumumab, and autologous stem cell transplantation (Abstract S180).

Multiple Myeloma

Cristina Gasparetto, MD, on Multiple Myeloma: Selinexor, Carfilzomib, and Dexamethasone in Carfilzomib-Nonrefractory Patients

Cristina Gasparetto, MD, of Duke University, discusses findings from a study that suggests patients with heavily pretreated multiple myeloma benefit from weekly selinexor, carfilzomib, and dexamethasone, which was reported to be active, with an overall response rate of 78% and an overall progression-free survival of 23 months (Abstract S188).

Hematologic Malignancies

Ruben A. Mesa, MD, on Myelofibrosis, Transfusion Independence, and Momelotinib

Ruben A. Mesa, MD, of UT Health San Antonio Cancer Center, discusses new findings on momelotinib, a potent JAK1, JAK2, and ACVR1 inhibitor with clinical activity against hallmark features of myelofibrosis such as anemia and splenomegaly. Results showed that transfusion independence was associated with improved overall survival in patients who had received momelotinib (Abstract S202).

Advertisement

Advertisement




Advertisement